Kancera AB, of Stockholm, plans to begin a phase I trial to evaluate for KAND-567, an orally available small molecule that blocks CX3CR1, the Fractalkine receptor. The agent was shown in preclinical models to combat relapses in autoimmune disease and nerve inflammation and pain associated with chemotherapy.